Please wait while the document is loaded.

A02818
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No.
464
Session of
2019
INTRODUCED BY BROWN, HENNESSEY, DiGIROLAMO, PICKETT, SONNEY,
LONGIETTI, HILL-EVANS, FREEMAN, RYAN, MURT, SCHLEGEL CULVER,
BIZZARRO, MALAGARI, BOBACK, BURNS, SCHMITT, OWLETT,
CALTAGIRONE, MILLARD, KORTZ, READSHAW, HEFFLEY AND MOUL,
SEPTEMBER 5, 2019
REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 5, 2019
A RESOLUTION
Recognizing the month of September 2019 as "Polycystic Kidney
Disease Awareness Month" in Pennsylvania.
WHEREAS, Polycystic kidney disease (PKD) is a genetic disease
that is passed from an infected affected parent to child and
causes uncontrolled growth of cysts in the kidney; and
WHEREAS, PKD affects all racial and ethnic groups equally and
occurs equally in men and women; and
WHEREAS, Approximately 600,000 people in the United States
have PKD and it is the fourth leading cause of kidney failure;
and
WHEREAS, There are three types of PKD: autosomal dominant
(ADPKD), autosomal recessive (ARPKD) and acquired cystic (ACKD);
and
WHEREAS, ADPKD is the most common form of PKD, comprising
90% of all PKD cases, and it is passed from parent to child
genetically by dominant inheritance; and
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
WHEREAS, Symptoms of ADPKD typically begin between 30 and 40
years of age, but can begin as early as childhood; and
WHEREAS, ARPKD is passed from parent to child genetically by
recessive inheritance; and
WHEREAS, ARPKD is a rare form of PKD and occurs in 1 in
20,000 children worldwide; and
WHEREAS, Symptoms of ARPKD begin in the earliest months of
life, even in the womb; and
WHEREAS, ARPKD is very serious because it progresses rapidly
and is often fatal in the first few months of life; and
WHEREAS, ACKD is most often associated with kidney failure
and dialysis because it can cause long-term damage and severe
scarring in the kidney; and
WHEREAS, ACKD develops in about 90% of people who have been
on dialysis for at least five years; and
WHEREAS, Symptoms that may indicate that an individual has
PKD include back or side pain, an increase in the size of the
abdomen, blood in the urine, frequent bladder or kidney
infections, fluttering or pounding in the chest and high blood
pressure; and
WHEREAS, High blood pressure is the most common sign of PKD;
and
WHEREAS, If high blood pressure is treated, the treatment can
help slow or even prevent kidney failure; and
WHEREAS, Approximately 50% of individuals with PKD will have
kidney failure by 60 years of age, and 60% of individuals will
have kidney failure by 70 years of age; and
WHEREAS, The only options available for individuals
experiencing kidney failure are dialysis or a kidney transplant;
and
A02818 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
WHEREAS, Although PKD has no cure, supportive treatments can
be administered to control symptoms, help slow cyst growth and
prevent or slow down the loss of kidney function as a result of
PKD; and
WHEREAS, Supportive treatments for PKD include all of the
following:
(1) Carefully controlling blood pressure.
(2) Promptly treating bladder or kidney infections with
antibiotics.
(3) Drinking a lot of water when blood in the urine is
first noticed.
(4) Using medication to control pain.
(5) Maintaining a healthy lifestyle by quitting smoking,
exercising, controlling weight, avoiding caffeine and
reducing salt intake;
and
WHEREAS, The average annual cost per patient of dialysis
treatments is $89,000, and the average total annual cost of
dialysis treatments is $42 billion nationwide; therefore be it
RESOLVED, That the House of Representatives recognize the
month of September 2019 as "Polycystic Kidney Disease Month" in
Pennsylvania.
A02818 - 3 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22